TABLE A1.
Additional Baseline Demographics and Disease Characteristics
| Characteristic | Patients With PD-L1 CPS ≥5 | All Patients | ||
|---|---|---|---|---|
| Nivolumab Plus Chemotherapy (n = 473) | Chemotherapy (n = 482) | Nivolumab Plus Chemotherapy (n = 789) | Chemotherapy (n = 792) | |
| PD-L1 CPS expression | ||||
| <1 | — | — | 140 (18) | 125 (16) |
| ≥1 | — | — | 641 (81) | 656 (83) |
| <5 | — | — | 308 (39) | 299 (38) |
| ≥5 | — | — | 473 (60) | 482 (61) |
| Not evaluable/indeterminate/missing | — | — | 8 (1) | 11 (1) |
| Albumin | ||||
| <LLN | 107 (23) | 116 (24) | 180 (23) | 178 (22) |
| ≥LLN | 350 (74) | 347 (72) | 577 (73) | 581 (73) |
| Not reported | 16 (3) | 19 (4) | 32 (4) | 33 (4) |
| Previous adjuvant or neoadjuvant therapy | ||||
| Adjuvant | 39 (8) | 27 (6) | 64 (8) | 56 (7) |
| Neoadjuvant | 26 (5) | 37 (8) | 48 (6) | 62 (8) |
| Metastatic disease | 0 | 0 | 1 (<1) | 0 |
NOTE. Data are No. (%).
Abbreviations: CPS, combined positive score; LLN, lower limit of normal.